Expression of MIG/CXCL9 in cystic fibrosis and modulation of its activities by elastase of Pseudomonas aeruginosa

Journal of Innate Immunity

Volumn 6, Issue 6, 2014, Pages 846-859

  Jovic, Sandra ^a   Shikhagaie, Medya ^a   Mörgelin, Matthias ^a   Kjellström, Sven ^b   Erjefalt, Jonas ^a   Olin, Anders I ^a   Frick, Inga Maria ^a   Egesten, Arne ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Cystic fibrosis; Host defense; MIG CXCL9 chemokine; Pseudomonas aeruginosa

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; ELASTASE; BACTERIAL PROTEIN; CXCL9 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN; METALLOPROTEINASE; PSEUDOLYSIN, PSEUDOMONAS AERUGINOSA;

ADULT; AGED; ANIMAL CELL; ARTICLE; BACTERIAL COLONIZATION; BACTERICIDAL ACTIVITY; BRONCHUS MUCOSA; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME RELEASE; FEMALE; HOST RESISTANCE; HUMAN; HUMAN TISSUE; LUNG PARENCHYMA; MALE; MAST CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PH; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; SPUTUM; T LYMPHOCYTE ACTIVATION; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOLOGY; PROTEIN DEGRADATION;

BACTERIAL PROTEINS; CHEMOKINE CXCL9; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; METALLOENDOPEPTIDASES; PROTEOLYSIS; PSEUDOMONAS AERUGINOSA; RECEPTORS, CXCR3; SPUTUM;

EID: 84908610311     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000365399     Document Type: Article

References (35)

1. O'Sullivan BP, Freedman SD: Cystic fibrosis. Lancet 2009; 373:1891-1904.
2. Hartl D, Gaggar A, Bruscia E., Hector A, Marcos V, Jung A., Greene C, McElvaney G, Mall M, Doring G: Innate immunity in cystic fibro-sis lung disease. J Cyst Fibros 2012; 11:363-382.
3. Mariencheck WI, Alcorn JF, Palmer S.M., Wright JR: Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am J Respir Cell Mol Biol 2003; 28:528-537.
4. Singh PK, Tack BF, McCray PB Jr, Welsh MJ: Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 2000; 279:L799-L805.
5. Hartl D, Griese M, Kappler M., Zissel G, Reinhardt D, Rebhan C., Schendel DJ, Krauss-Etschmann S: Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006; 117:204-211.
6. Tiringer K, Treis A, Fucik P., Gona M, Gruber S, Renner S., Dehlink E, Nachbaur E, Horak F, Jaksch P, et al.: A Th17- and Th2-skewed cy-tokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2013; 187:621-629.
7. Smith JJ, Travis SM, Greenberg E.P., Welsh MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229-236.
8. Joris L, Dab I, Quinton PM: Elemental composition of human airway surface fluid in healthy and diseased airways. Am Rev Respir Dis 1993; 148:1633-1637.
9. Matsui H, Grubb BR, Tarran R, Randell S.H., Gatzy JT, Davis C W, Boucher RC: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fi-brosis airways disease. Cell 1998; 95: 1005-1015.
10. Guggino WB: Cystic fibrosis and the salt controversy. Cell 1999; 96:607-610.
11. Goldman MJ, Anderson GM, Stolzenberg E.D., Kari UP, Zasloff M, Wilson JM: Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88:553-560.
12. Bals R, Wang X, Wu Z., Freeman T, Bafna V, Zasloff M., Wilson JM: Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998; 102:874-880.
13. Chen JH, Stoltz DA, Karp P.H., Ernst SE, Pezzulo AA, Moninger TO, Rector M V, Reznikov LR, Launspach JL, Chaloner K, et al.: Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 2010; 143:911-923.
14. Pezzulo AA, Tang XX, Hoegger M.J., Alaiwa MH, Ramachandran S, Moninger TO, Karp P.H., Wohlford-Lenane CL, Haagsman HP, van Eijk M, et al.: Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012; 487:109-113.
15. Coakley RD, Grubb BR, Paradiso A.M., Gatzy JT, Johnson LG, Kreda SM, O'Neal WK, Boucher RC: Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. Proc Natl Acad Sci USA 2003; 100:16083-16088.
16. Linge HM, Collin M, Giwercman A., Malm J, Bjartell A, Egesten A: The antibacterial che-mokine MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in seminal plasma. J Interfer Cytok Res 2008; 28:191-196.
17. Cole AM, Ganz T, Liese A.M., Burdick MD, Liu L, Strieter RM: IFN-inducible ELR-CXC che-mokines display defensin-like antimicrobial activity. J Immunol 2001; 167:623-627.
18. Cole KE, Strick CA, Paradis T.J., Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd J.G., Moser B., Wood DE, Sahagan BG, Neote K: Interferon-inducible T cell alpha chemoat-tractant (I-TAC): a novel non-ELR CXC che-mokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187:2009-2021.
19. Egesten A, Eliasson M, Johansson H.M., Olin AI, Morgelin M, Mueller A, Pease J.E., Frick IM, Bjorck L: The CXC chemokine MIG/ CXCL9 is important in innate immunity against Streptococcus pyogenes. J Infect Dis 2007; 195:684-693.
20. Crawford MA, Burdick MD, Glomski I.J., Boyer AE, Barr JR, Mehrad B, Strieter R.M., Hughes MA: Interferon-inducible CXC chemokines directly contribute to host defense against in-halational anthrax in a murine model of infection. PLoS Pathog 2010; 6:e1001199.
21. Nordin SL, Andersson C, Bjermer L., Bjartell A, Mörgelin M, Egesten A: Midkine is part of the antibacterial activity released at the surface of differentiated bronchial epithelial cells. J Innate Immun 2013; 5:519-530.
22. Holloway BW: Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol 1955; 13:572-581.
23. Stover CK, Pham XQ, Erwin A.L., Mizoguchi SD, Warrener P, Hickey MJ, Brinkman F.S., Hufnagle WO, Kowalik DJ, Lagrou M, et al.: Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406:959-964.
24. Carlsson M, Shukla S, Petersson A.C., Segelmark M., Hellmark T: Pseudomonas aerugi-nosa in cystic fibrosis: pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease. J Cyst Fibros 2011; 10:265-271.
25. Schwede T, Kopp J, Guex N., Peitsch MC: Swiss-model: an automated protein homolo-gy-modeling server. Nucleic Acids Res 2003; 31:3381-3385.
26. Erdjument-Bromage H, Lui M, Sabatini D.M., Snyder SH, Tempst P: High-sensitivity sequencing of large proteins: partial structure of the rapamycin-FKBP12 target. Protein Sci 1994; 3:2435-2446.
27. Cole KE, Strick CA, Paradis T.J., Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd J.G., Moser B., Wood DE, Sahagan BG, Neote K: Interferon-inducible T cell chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187:2009-2021.
28. Clark-Lewis I, Mattioli I, Gong J.H., Loetscher P: Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 2003; 278: 289-295.
29. Nordin SL, Jovic S, Kurut A., Andersson C, Gela A, Bjartell A., Morgelin M, Olin AI, Lund M, Egesten A: High expression of mid-kine in the airways of patients with cystic fibrosis. Am J Respir Cell Mol Biol 2013; 49: 935-942.
30. Clark-Lewis I, Mattioli I, Gong J.H., Loetscher P: Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 2003; 278: 289-295.
31. Colvin RA, Campanella GS, Sun J, Luster AD: Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 2004; 279:30219-30227.
32. Proost P, Schutyser E, Menten P., Struyf S, Wuyts A, Opdenakker G., Detheux M, Par-mentier M, Durinx C, Lambeir AM, et al.: Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving anti-angiogenic properties. Blood 2001; 98: 3554-3561.
33. Tupin E, Kinjo Y, Kronenberg M: The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 2007; 5: 405-417.
34. Xu X, Zhang D, Lyubynska N., Wolters PJ, Killeen NP, Baluk P, McDonald D.M., Haw-good S, Caughey GH: Mast cells protect mice from mycoplasma pneumonia. Am J Respir Crit Care Med 2006; 173:219-225.
35. Siebenhaar F, Syska W, Weller K., Magerl M, Zuberbier T, Metz M., Maurer M: Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent. Am J Pathol 2007; 170:1910-1916.